Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T19:17:51.767Z.
Calculation as of: 2026-10-06T19:17:51.767Z.
Quote observation: 2026-10-06T19:15:28.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ffce46548baf09eb68ba264c0fe19ed309a9d25018129ed05cb07bb19ae3cea1
PEG RATIO
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Novocure Ltd (NVCR) | $1.76B | N/A | N/A | N/A | N/A |
| Absci Corporation (ABSI)vs › | $1.77B | N/A | N/A | N/A | N/A |
| Surgery Partners, Inc. (SGRY)vs › | $1.77B | N/A | N/A | N/A | N/A |
| Alignment Healthcare, Inc. (ALHC)vs › | $1.73B | N/A | N/A | N/A | N/A |
| Xencor, Inc. (XNCR)vs › | $1.79B | N/A | 3.15 | 3.15 | 3.15 |
| Generate Biomedicines, Inc. (GENB)vs › | $1.79B | N/A | N/A | N/A | N/A |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.73B | N/A | N/A | N/A | N/A |
| Xeris Biopharma Holdings, Inc. (XERS)vs › | $1.73B | N/A | N/A | N/A | N/A |
| LeMaitre Vascular, Inc. (LMAT)vs › | $1.81B | 1.44 | 2.03 | 10.26 | 11.33 |
| Sarepta Therapeutics, Inc. (SRPT)vs › | $1.82B | N/A | N/A | N/A | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
